Biotech | November 26, 2025
Novartis scores FDA nod for game-changing SMA treatment
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
IND application for EB-003 expected in early 2026
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Athena is also exploring the use of this technology for expanded carrier screening
Parkinson's disease (PD) is one of the most common neurological disorders caused by the death of dopamine-secreting neurons in the brain
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
Subscribe To Our Newsletter & Stay Updated
